(Q28274721)

1

0 references

Xiao-Di Xu

2

0 references

Qiong Huang

3

0 references

Hua Wu

Rheumatology International

4

0 references

language of work or name

English

0 references

publication date

February 2013

0 references

published in

0 references

volume

33

0 references

issue

2

0 references

page(s)

273-6

0 references

cites work

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide: mode of action in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Vasculitis occurring during leflunomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Peripheral neuropathy: an unwanted effect of leflunomide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide induced vasculitis--a dose-response relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide-associated pancytopenia with or without methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Peripheral neuropathy in patients on leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Peripheral neuropathy in patients treated with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Subacute cutaneous lupus erythematosus associated with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide-induced subacute cutaneous lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Lupus erythematosus with leflunomide: induction or reactivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-012-2508-Z

Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis

21 January 2018

1 reference

12 December 2020

Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.

1 reference

12 December 2020

Leflunomide induced acute interstitial pneumonia.

1 reference

12 December 2020

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

1 reference

12 December 2020

Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story

1 reference

12 December 2020

Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

12 December 2020

Subacute cutaneous lupus erythematosus precipitated by leflunomide

1 reference

12 December 2020

The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery

1 reference

12 December 2020

Leflunomide in systemic lupus erythematosus

1 reference

12 December 2020